Somatrogon: First Approval

[1]  N. Mauras,et al.  Results From an Open-Label Extension of the Phase 2 Dose Finding Study of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency (GHD) , 2021, Journal of the Endocrine Society.

[2]  M. Dattani,et al.  Perception of Treatment Burden With Once Weekly Somatrogon vs Once Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency (GHD): Results From a Randomized Phase 3 Study , 2021 .

[3]  M. Phillip,et al.  Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (pGHD) , 2021 .

[4]  Toshiaki Tanaka,et al.  Phase 3 Study Evaluating Once Weekly Somatrogon Compared to Daily Genotropin in Japanese Patients With Pediatric Growth Hormone Deficiency (pGHD) , 2021, Journal of the Endocrine Society.

[5]  A. Hoffman,et al.  Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs , 2021, Frontiers in Endocrinology.

[6]  V. Iotova,et al.  Long-Term Safety of a Once-Weekly Somatrogon (hGH-CTP): 4-Year Results of a Phase 2 Extension Study in Children with Growth Hormone Deficiency , 2019 .

[7]  G. Jaczko,et al.  Pfizer Inc. , 2018, The Grants Register 2019.

[8]  V. Iotova,et al.  Long-Acting C-Terminal Peptide–Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children , 2017, The Journal of clinical endocrinology and metabolism.

[9]  Michal Jaron-Mendelson,et al.  Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children , 2017, Hormone Research in Paediatrics.

[10]  V. Hwa,et al.  In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone. , 2016, Molecular pharmaceutics.